M. J. Ryan

发表

Evaluation of physicochemical parameters important to the oral bioavailability of peptide-like compounds: implications for the synthesis of renin inhibitors.

O. H. Chan, C. J. Blankley, H. W. Hamilton, 1995, Journal of medicinal chemistry.

Discovery of 6-ethyl-2,4-diaminopyrimidine-based small molecule renin inhibitors.

N. Powell, M. J. Ryan, E. Zhang, 2007, Bioorganic & medicinal chemistry letters.

Equipotent activity in both enantiomers of a series of ketopiperazine-based renin inhibitors.

N. Powell, M. J. Ryan, E. Zhang, 2005, Bioorganic & medicinal chemistry letters.

N6-substituted adenosine receptor agonists: potential antihypertensive agents.

C. J. Blankley, H. W. Hamilton, M. J. Ryan, 1991, Journal of medicinal chemistry.

Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.

N. Powell, M. J. Ryan, E. Zhang, 2007, Bioorganic & medicinal chemistry.

Benzyl ether structure-activity relationships in a series of ketopiperazine-based renin inhibitors.

N. Powell, M. J. Ryan, M. Jalaie, 2005, Bioorganic & medicinal chemistry letters.

Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitors.

A. Doherty, M. J. Ryan, M. Taylor, 1992, Journal of medicinal chemistry.

Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors.

A. Doherty, H. W. Hamilton, B. Steinbaugh, 1992, Journal of medicinal chemistry.

TETRAHYDROISOQUINOLINE AS A PHENYLALANINE REPLACEMENT IN RENIN INHIBITORS

E. Lunney, H. W. Hamilton, B. Steinbaugh, 1994 .

Evaluation of the intestinal permeability and hepatic handling of peptidomimetic analogs

O. H. Chan, H. W. Hamilton, B. Steinbaugh, 1993 .

Orally active water-soluble N,O-acyl transfer products of a beta,gamma-bishydroxyl amide containing renin inhibitor.

M. J. Ryan, G. Hicks, T. Hurley, 1993, Journal of medicinal chemistry.

Antihypertensive effects of CI-907 (indolapril): a novel nonsulfhydryl angiotensin converting enzyme inhibitor.

T. Major, M. J. Ryan, D. Boucher, 1984, The Journal of pharmacology and experimental therapeutics.

CI-926 (3-[4-[4-(3-methylphenyl)-1-piperazinyl]butyl]-2,4-imidazolinedione): antihypertensive profile and pharmacology.

D. B. Evans, T. Major, M. J. Ryan, 1986, Journal of Pharmacology and Experimental Therapeutics.